ARS Pharma holder plans $273K stock sale Sep. 1

ARS Pharmaceuticals, Inc. (SPRY) received a Form 144 notice indicating that stockholder Sarina Tanimoto plans to sell up to 45,388 shares of common stock, to be acquired via a stock option exercise and sold for cash through Morgan Stanley Smith Barney LLC.

Rhea-AI Filing Summary

ARS Pharmaceuticals, Inc. (SPRY) received a Form 144 notice indicating that stockholder Sarina Tanimoto plans to sell up to 45,388 shares of common stock, to be acquired via a stock option exercise and sold for cash through Morgan Stanley Smith Barney LLC. The planned sale date is listed as September 1, 2026. The notice also reports multiple prior sales of ARS Pharmaceuticals common stock by the same holder during the preceding three months.

Key Figures

Shares proposed to be sold: 45,388 shares of common stock Aggregate market value of proposed sale: $272,849.96 Proposed sale date: 09/01/2026 +4 more

7 metrics

Shares proposed to be sold 45,388 shares of common stock Planned Rule 144 sale by Sarina Tanimoto

Aggregate market value of proposed sale $272,849.96 Value associated with 45,388 shares to be sold

Proposed sale date 09/01/2026 Date for planned Rule 144 sale

Shares sold on 08/18/2026 49,401 shares Common stock sold by Sarina Tanimoto for $311,191.72

Shares sold on 08/19/2026 25,000 shares Common stock sold by Sarina Tanimoto for $161,170.00

Shares sold on 08/20/2026 25,000 shares Common stock sold by Sarina Tanimoto for $147,970.00

Shares sold on 08/31/2026 63,289 shares Common stock sold by Sarina Tanimoto for $368,099.12

Key Terms

Form 144, Rule 144, Stock Option Exercise, Aggregate market value

4 terms

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 09/01/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 45388 | 272849.96"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 144 filing mean for ARS Pharmaceuticals (SPRY)?

The filing reports that stockholder Sarina Tanimoto plans to sell up to 45,388 shares of ARS Pharmaceuticals common stock under Rule 144 after exercising stock options. It is a notice of a potential resale by an existing holder, not a new share issuance by the company.

How many ARS Pharmaceuticals (SPRY) shares are proposed to be sold in this Form 144?

The notice states that up to 45,388 shares of common stock of ARS Pharmaceuticals may be sold. These shares are tied to a stock option exercise and are to be sold for cash through Morgan Stanley Smith Barney LLC.

What is the proposed sale date and aggregate value in the ARS Pharmaceuticals (SPRY) Form 144?

The proposed sale date is September 1, 2026, and the aggregate market value shown for the 45,388 shares is $272,849.96, based on the information provided in the Form 144 notice.

What ARS Pharmaceuticals (SPRY) stock sales has the filer made in the past three months?

The filer reports prior common stock sales of 49,401 shares on 08/18/2026 for $311,191.72, 25,000 shares on 08/19/2026 for $161,170.00, 25,000 shares on 08/20/2026 for $147,970.00, and 63,289 shares on 08/31/2026 for $368,099.12.

Who is the selling security holder in this ARS Pharmaceuticals (SPRY) Form 144?

The selling security holder is Sarina Tanimoto. The Form 144 lists her as the person for whose account the securities are to be sold and includes her prior three-month sale history of ARS Pharmaceuticals common stock.

Is ARS Pharmaceuticals (SPRY) itself selling shares in this Form 144?

No. The Form 144 describes resales by an existing stockholder, Sarina Tanimoto, including shares to be obtained via stock option exercise. It does not describe ARS Pharmaceuticals issuing new shares for its own account.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:52 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:52 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001951291
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARS PHARMACEUTICALS, INC.
SEC File Number	001-39756
Address of Issuer	11682 El Camino Real Suite 300 San Diego CALIFORNIA 92130
Phone	(858) 771-9307
Name of Person for Whose Account the Securities are To Be Sold	SARINA TANIMOTO
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	45388	272849.96	99447343	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2026	Stock Option Exercise	Issuer			45388	09/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SARINA TANIMOTO 11682 El Camino Real Suite 300 San Diego CA 92130	Common	08/31/2026	63289	368099.12
SARINA TANIMOTO 11682 El Camino Real Suite 300 San Diego CA 92130	Common	08/20/2026	25000	147970.00
SARINA TANIMOTO 11682 El Camino Real Suite 300 San Diego CA 92130	Common	08/19/2026	25000	161170.00
SARINA TANIMOTO 11682 El Camino Real Suite 300 San Diego CA 92130	Common	08/18/2026	49401	311191.72

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sarina Tanimoto
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)